olaparib (Lynparza) PARP Inhibitor especially effective for BRCA ER/PR+ HER2-

This is a promising future treatment option now that it has been approved.

http://www.cancerresearchuk.org/about-us/cancer-news/news-report/2017-06-04-ovarian-cancer-drug-reduces-chance-certain-advanced-breast-cancers-will-get-worse

and more on this:

http://am.asco.org/olaparib-improves-outcomes-brca-mutated-metastatic-breast-cancer?j=39315720&sfmc_sub=990554367&l=18416124_HTML&u=670649578&mid=10831468&jb=65&et_cid=39315720&et_rid=990554367&linkid=BRCA

 

Advertisements

Author: Becky

I'm a Ph.D candidate, associate lecturer, and breast cancer survivor. I'm studying how patients develop health literacy.

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s